Company Gilead Sciences, Inc.

GILD

US3755581036

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:15:00 18/06/2025 BST			After hours 21:48:26
108.00 ^USD	0.00%		108.24	+0.22%

09:49pm	US FDA approves Gilead's twice-yearly injection for HIV prevention	RE
08:39pm	Gilead Sciences' Twice-Yearly HIV-Prevention Drug Gets FDA Approval	DJ

Business description: Gilead Sciences, Inc.

Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:

- sale of drugs (99.5%): for the treatment of HIV (68.5% of net sales), oncology diseases (11.5%), hepatitis B virus (10.6%), Ebola virus (6.3%) and other (3.1%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);

- other (0.5%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.

Net sales are distributed geographically as follows: the United States (71.6%), Europe (16.1%) and other (12.3%).

Number of employees: 17,600

Sales by Activity: Gilead Sciences, Inc.

Fiscal Period: December	2020	2021	2022	2023	2024
Discovery, Development and Commercialization of Innovative Medicines	24.69B	27.3B	27.28B	27.12B	28.75B

See all business segments

Geographical breakdown of sales: Gilead Sciences, Inc.

Fiscal Period: December	2020	2021	2022	2023	2024
United States	18.22B	19.27B	18.88B	19.44B	20.59B
Europe	4.14B	4.87B	4.47B	4.31B	4.63B
Rest of World	2.34B	3.16B	3.93B	3.37B	3.53B

See all geographic segments

Executive Committee: Gilead Sciences, Inc.

Manager	Title	Age	Since
Daniel O'Day CEO	Chief Executive Officer	60	28/02/2019
Andrew Dickinson DFI	Director of Finance/CFO	55	31/10/2019
Dietmar Berger CTO	Chief Tech/Sci/R&D Officer	-	01/01/2025
Jacquie Ross IRC	Investor Relations Contact	-	31/12/2020
Robert Cook PRN	Corporate Officer/Principal	66	29/02/2012

See GILEAD SCIENCES, INC. governance

Composition of the Board of Directors: Gilead Sciences, Inc.

Director	Title	Age	Since
Kelly Kramer BRD	Director/Board Member	57	18/08/2016
Jacqueline Barton BRD	Director/Board Member	72	31/12/2017
Harish M. Manwani BRD	Director/Board Member	71	08/05/2018
Daniel O'Day CHM	Chairman	60	28/02/2019
Sandra Horning BRD	Director/Board Member	76	27/01/2020
Javier Rodriguez BRD	Director/Board Member	54	14/06/2020
Anthony Welters BRD	Director/Board Member	70	16/10/2020
Jeffrey Bluestone BRD	Director/Board Member	71	06/12/2020
Ted Love BRD	Director/Board Member	66	31/01/2024

Composition of the Board of Directors

Shareholders: Gilead Sciences, Inc.

Name	Equities	%	Valuation
Vanguard Fiduciary Trust Co. 9.426 %	117,470,825	9.426 %	12 931 M $
BlackRock Advisors LLC 6.807 %	84,831,105	6.807 %	9 338 M $
STATE STREET CORPORATION 4.776 %	59,523,675	4.776 %	6 552 M $
Fidelity Management & Research Co. LLC 4.694 %	58,499,955	4.694 %	6 440 M $
Capital Research & Management Co. (Global Investors) 4.382 %	54,610,370	4.382 %	6 012 M $

Name	Equities	%	Valuation
BRAM - Bradesco Asset Management SA DTVM 0.000215 %	5,370	0.000215 %	286 269 $

List of GILEAD SCIENCES, INC. shareholders

Holdings: Gilead Sciences, Inc.

Name	Equities	%	Valuation
GALAPAGOS NV 25.35%	16,707,477	25.35%	486,697,493 $
ARCELLX, INC. 12.43%	6,720,803	12.43%	417,093,034 $
ARCUS BIOSCIENCES, INC. 29.69%	31,424,760	29.69%	280,623,107 $
ASSEMBLY BIOSCIENCES, INC. 34.76%	2,209,471	34.76%	31,264,015 $
MERUS N.V. 0.66%	452,527	0.66%	25,373,189 $
TANGO THERAPEUTICS, INC. 4.52%	4,854,443	4.52%	10,776,863 $
KYVERNA THERAPEUTICS, INC. 9.56%	4,126,119	9.56%	10,521,603 $
XILIO THERAPEUTICS, INC. 19.9%	9,105,451	19.9%	9,742,833 $
HOOKIPA PHARMA INC. 19.43%	1,875,945	19.43%	2,982,753 $
HOOKIPA PHARMA INC. 3.87%	723,273	3.87%	2,097,492 $

Company details: Gilead Sciences, Inc.

Gilead Sciences, Inc.

333 Lakeside Drive

94404, Foster City

+650 574 3000

http://www.gilead.com

Group companies: Gilead Sciences, Inc.

Name	Category and Sector
Gilead Sciences Ireland UC Gilead Sciences Ireland UC Pharmaceuticals: MajorHealth Technology Part of Gilead Sciences, Inc., Gilead Sciences Ireland UC engages in discovering, developing, and delivering innovative therapeutics for life-threatening diseases. The company is based in Carrigtwohill, Ireland.	Pharmaceuticals: Major
Gilead Therapeutics A1 Unlimited Co. Gilead Therapeutics A1 Unlimited Co. Pharmaceuticals: MajorHealth Technology Part of Gilead Sciences, Inc., Gilead Therapeutics A1 Unlimited Co. is an Irish company that develops and manufactures pharmaceutical medicines. The company is located in Ireland.	Pharmaceuticals: Major

See all subsidiaries

Other Pharmaceuticals

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
GILEAD SCIENCES, INC.	0.00%	-1.19%	+71.02%	+78.48%	134B
ELI LILLY AND COMPANY	-0.78%	-2.92%	-11.94%	+164.02%	710B
JOHNSON & JOHNSON	-1.08%	-2.92%	+3.49%	-12.88%	367B
NOVO NORDISK A/S	-1.13%	-7.18%	-50.79%	+29.17%	335B
ABBVIE INC.	+0.01%	-3.14%	+8.25%	+29.29%	328B
ROCHE HOLDING AG	-0.96%	-3.97%	+5.54%	-14.59%	258B
NOVARTIS AG	-0.63%	-2.66%	+1.53%	+20.25%	230B
ASTRAZENECA PLC	-1.07%	-2.98%	-15.13%	+6.29%	223B
MERCK & CO., INC.	+1.29%	-1.28%	-38.05%	-9.93%	197B
AMGEN INC.	-0.19%	-0.79%	-5.39%	+21.43%	156B
Average	-0.17%	-1.47%	-3.15%	+31.15%	293.69B
Weighted average by Cap.	-0.37%	-0.51%	-7.45%	+49.50%